

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 54071

Title: Efficacy of bevacizumab-containing chemotherapy in metastatic colorectal cancer and CXC expression: Six case reports

Reviewer's code: 03001969

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Lebanon

Author's Country/Territory: Spain

Manuscript submission date: 2020-01-07

Reviewer chosen by: Jie Wang

Reviewer accepted review: 2020-01-16 05:35

Reviewer performed review: 2020-01-17 05:46

Review time: 1 Day

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input checked="" type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input checked="" type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

In their report on six cases with KRAS mutated mCRC receiving CT plus bevacizumab treatment, the authors bring upon an important subject matter which is why some patients progress on CT plus bevacizumab while others benefit. Their finding concerning the possibility that the CXCL5 gene could be taking part in the resistance to bevacizumab is an important one which should be definitely investigated further. Concerning my comments, they are minor and are listed below. 1) concerning key words, please use MESH terms 2) define line 123 ALPSS 3) minor language errors: a)line 124-125: "In October 2017 and was admitted" change to "In October 2017, she was admitted..." b)line 143: "just for 3 months due to cardiac ischemia" change to "for only 3 months due to cardiac ischemia" c)line 154: "Patient characteristics were summarized in Table 1" change to "Patient characteristics are summarized in..." d)line 170-172: "Despite tumor progression" Please rephrase e)line 174: change "scare" to "scarce" f)line 175: replace "of the benefits" with "on the benefits" 4) I would suggest another table besides table 1 which would list each patient's case (case 1 through 6) with their CXCL5 value and their respective PFS. Then at the end of the table you could add the overall CXCL5 and PFS which you did in table 1.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

BPG Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No